No headlines found.
Globe Newswire (Tue, 7-Apr 8:15 AM ET)
Globe Newswire (Mon, 30-Mar 8:00 AM ET)
Globe Newswire (Thu, 19-Mar 8:00 AM ET)
Globe Newswire (Thu, 5-Mar 8:00 AM ET)
Globe Newswire (Wed, 4-Mar 8:00 AM ET)
BioRestorative Announces Closing of $5.0 Million Public Offering
Globe Newswire (Fri, 13-Feb 8:30 PM ET)
BioRestorative Announces Pricing of $5.0 Million Public Offering
Globe Newswire (Wed, 11-Feb 10:30 PM ET)
BioRestorative Announces Positive Outcome from Type B Meeting with FDA
Globe Newswire (Wed, 11-Feb 7:30 AM ET)
Globe Newswire (Tue, 10-Feb 8:00 AM ET)
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
Biorestorative Therapies trades on the NASDAQ stock market under the symbol BRTX.
As of April 7, 2026, BRTX stock price was flat at $0.25 with 1,948,006 million shares trading.
BRTX has a beta of 0.77, meaning it tends to be less sensitive to market movements. BRTX has a correlation of 0.01 to the broad based SPY ETF.
BRTX has a market cap of $6.39 million. This is considered a Sub-Micro Cap stock.
Last quarter Biorestorative Therapies reported $19,600 in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-150,400 and exceeded earnings estimates by $.05.
In the last 3 years, BRTX traded as high as $7.13 and as low as $.19.
The top ETF exchange traded funds that BRTX belongs to (by Net Assets): VXF.
BRTX has underperformed the market in the last year with a price return of -85.3% while the SPY ETF gained +31.9%. BRTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -78.6% and -23.3%, respectively, while the SPY returned -4.5% and +0.6%, respectively.
BRTX support price is $.23 and resistance is $.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRTX shares will trade within this expected range on the day.